흡입 일산화질소 전달 시스템 : 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Inhaled Nitric Oxide Delivery System Market was valued at USD 358.7 million in 2024 and is estimated to grow at a CAGR of 5.6% to reach USD 615.6 million by 2034. The market is witnessing notable growth as respiratory conditions like acute respiratory distress syndrome (ARDS), persistent pulmonary hypertension, and hypoxic respiratory failure continue to rise across various age groups. Inhaled nitric oxide (iNO) has emerged as a vital therapeutic option due to its vasodilatory effects, helping improve oxygenation and reducing the need for more invasive respiratory support. The increasing burden of respiratory illnesses, both in developed and developing regions, is pushing healthcare facilities to adopt advanced treatment modalities that are safe, effective, and cost-efficient. With the growing emphasis on precision and non-invasive therapies in respiratory care, inhaled nitric oxide systems are becoming a preferred choice across neonatal intensive care units (NICUs), pediatric ICUs, and adult critical care settings. Additionally, enhanced access to healthcare infrastructure and an increasing focus on early diagnosis and intervention have led to higher adoption of inhaled nitric oxide delivery systems globally. The market's growth is further supported by the rising number of clinical studies validating the efficacy of iNO therapy, regulatory approvals for innovative delivery devices, and a shift toward personalized medicine in treating pulmonary complications.

The market is segmented by age groups, including neonatal, pediatric, and adult categories. Among these, the neonatal segment stood out prominently, reaching a valuation of USD 221.2 million in 2024 and projected to grow to USD 384.2 million by 2034. This growth is fueled by the rising incidence of neonatal respiratory distress, especially among premature newborns. Inhaled nitric oxide therapy is frequently administered to improve pulmonary function and reduce the need for extracorporeal life support. The increasing rate of preterm births, combined with advancements in neonatal care technology and improved NICU facilities in emerging economies, is further accelerating demand within this segment.

In terms of application, hypoxic respiratory failure held the largest market share at 55.3% in 2024 and is expected to grow at a CAGR of 4.7% through 2034. This condition is commonly seen in both neonatal and pediatric patients and inhaled nitric oxide offers a more accessible and cost-effective treatment option compared to invasive procedures like extracorporeal membrane oxygenation (ECMO). Its ease of use, minimal side effects, and positive outcomes in critical care scenarios are driving its preference across pediatric and neonatal settings.

The U.S. Inhaled Nitric Oxide Delivery System Market was valued at USD 127.6 million in 2024 and continues to expand steadily. The growing number of ARDS cases among newborns, coupled with high awareness and availability of advanced respiratory care infrastructure, supports strong market uptake. Widespread adoption across hospital and NICU environments underscores the country's leadership in this space.

Key players shaping the global inhaled nitric oxide delivery system landscape include Merck KGaA, Air Liquide Healthcare, Linde, Bellerophon Therapeutics, Getinge, Beyond Air, Praxair, Baxter International, Mallinckrodt Pharmaceuticals, Circassia Pharmaceuticals, EKU Elektronik, VERO Biotech, International Biomedical, SLE, and NU-MED Plus. These companies are prioritizing innovation through the development of next-generation delivery systems, expanding their geographic footprint, and forming strategic alliances. Their focus remains on enhancing therapy efficiency, improving patient outcomes, and navigating regulatory pathways through collaborations with healthcare institutions and research bodies.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of respiratory diseases
    • 3.2.1.2 Technological advancements in inhaled nitric oxide delivery systems
    • 3.2.1.3 Increased awareness among healthcare professionals and patients
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with inhaled nitric oxide therapy
    • 3.2.2.2 Presence of stringent regulations
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Gap analysis
• 3.7 Patent analysis
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Neonatal
• 5.3 Pediatric
• 5.4 Adult

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hypoxic respiratory failure
• 6.3 Acute hypoxemic respiratory failure
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Disposables
• 7.3 System

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory centers
• 8.4 Clinics

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Air Liquide Healthcare
• 10.2 Baxter International
• 10.3 Bellerophon Therapeutics
• 10.4 Beyond Air
• 10.5 Circassia Pharmaceuticals
• 10.6 EKU Elektronik
• 10.7 Getinge
• 10.8 International Biomedical
• 10.9 Linde
• 10.10 Mallinckrodt Pharmaceuticals
• 10.11 Merck KGaA
• 10.12 NU-MED Plus
• 10.13 Praxair
• 10.14 SLE
• 10.15 VERO Biotech